The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

(2017) Prakash Chinnaiyan et al.   NEURO-ONCOLOGY

Corticosteroids compromise survival in glioblastoma

(2016) Kenneth L. Pitter et al.   BRAIN

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

(2016) W. Wick et al.   CLINICAL CANCER RESEARCH

GlioVis data portal for visualization and analysis of brain tumor expression datasets

(2016) Robert L. Bowman et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid

(2014) Sebastian Fischer et al.   PLoS One

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

(2013) M. Weiler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells

(2012) Caroline Happold et al.   JOURNAL OF NEUROCHEMISTRY

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2α

(2010) Sascha Seidel et al.   BRAIN

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives

(2010) Michael W. Ronellenfitsch et al.   Targeted Oncology

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death

(2009) Michael W. Ronellenfitsch et al.   BRAIN

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

(2009) A. Rapisarda et al.   MOLECULAR CANCER THERAPEUTICS

Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling

(2008) M. P. DeYoung et al.   GENES & DEVELOPMENT